About News Center Qualitest Continues Growth Trajectory, Acquires Comply to Expand Pharma and Digital Health Footprint


Qualitest Continues Growth Trajectory, Acquires Comply to Expand Pharma and Digital Health Footprint

Bridgepoint backs acquisition that brings pharma giants Teva, Merck, Johnson & Johnson, and others into Qualitest’s client portfolio.
April 7, 2021

London – April 7, 2021 – Qualitest, the world’s leading AI-powered, engineering-driven software testing and quality assurance company, announced today the acquisition of Israel-based Comply, a quality assurance specialist in Pharma and Digital Health.

Qualitest operates in a market that is growing at a 10% annual rate driven by the increasing needs of a $32 billion global outsourced market. The deal is expected to close this week. This is Qualitest’s second high-profile acquisition in 2021 and reinforces the company’s stronghold in the €8 billion medical technology testing market.

The deal will add 83 of Comply’s employees into the Qualitest team and will add Teva, Merck, Johnson & Johnson, GE Medical and AbbVie to Qualitest’s list of high-profile clients. Following the acquisition, Teva will become one of Qualitest’s leading pharmaceutical accounts globally.

As a strategic partner, Qualitest helps brands move beyond functional testing to adopt new innovations such as automation, AI and crowd sourced UX testing. It leverages its domain expertise across industries, including insurance and financial services, media and entertainment, retail, consumer goods, technology, gaming, telecom, aerospace, among others.

Founded in 2005, Comply provides quality assurance services for web, cloud and mobile applications related to digital health products. In particular, the company has focused on the validation of computerized systems, including enterprise IT and laboratory systems, as well as validation of IT infrastructure, such as information security and disaster recovery plans.

“We’ve had our eyes on Comply for a while due to its reputation as a leader in providing software testing services to the growing pharma tech market,” said Norm Merritt, Qualitest CEO. “That’s why we are excited to bring them into the Qualitest family. We see a lot of potential in the pharma industry, and by integrating Comply’s expertise we can expand Qualitest’s footprint in this hot-growth area,” he added.

“Qualitest is a global leader in testing, which is why it’s the perfect partner to help us take our testing services worldwide,” said Gai Anbar, Founder and CEO at Comply. “We have been impressed with Qualitest’s position as the go-to provider for software testing. By joining forces, we can capitalize on our own expertise in providing the highest quality assurance for health and pharma businesses,” he added.


About Qualitest:

Founded in 1997, Qualitest offers a wide range of AI-powered quality engineering and testing solutions, designed to mitigate the business risk associated with software releases. Qualitest achieves this by deploying engagement models tailored to the precise testing needs of technology platforms in the technology, financial services, retail, telecom, healthcare, insurance, aerospace, media and utilities industries. It has operations in Israel (where it was founded), the US, UK, and Romania, and serves over 250 blue-chip customers worldwide. Qualitest is majority-owned by international private equity group Bridgepoint, which acquired the company in October 2019 via its €5.7 billion flagship fund BE VI. To learn more about Qualitest, visit www.qualitestgroup.com.

Latest News